(Q36019817)

11 August 2017

1 reference

title

A critical appraisal of the role of insulin analogues in the management of diabetes mellitus (English)

1 reference

11 August 2017

1 reference

Ralph Oiknine

1

1 reference

11 August 2017

Marla Bernbaum

series ordinal

2

1 reference

11 August 2017

Arshag D Mooradian

series ordinal

3

1 reference

11 August 2017

publication date

1 January 2005

1 reference

11 August 2017

1 reference

11 August 2017

volume

65

1 reference

11 August 2017

issue

3

1 reference

11 August 2017

page(s)

325-340

1 reference

Effects of Rapid-Acting Insulin Analogs on Overall Glycemic Control in Type 1 and Type 2 Diabetes Mellitus

11 August 2017

cites work

1 reference

12 December 2020

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

1 reference

12 December 2020

Treating diabetes with aerosolized insulin

1 reference

12 December 2020

A novel insulin analog with unique properties: LysB3,GluB29 insulin induces prominent activation of insulin receptor substrate 2, but marginal phosphorylation of insulin receptor substrate 1.

1 reference

12 December 2020

A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes

1 reference

12 December 2020

Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus

1 reference

12 December 2020

Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus

1 reference

12 December 2020

Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir

1 reference

12 December 2020

Postprandial glycaemia after regular and lispro insulin in children and adolescents with diabetes

1 reference

12 December 2020

New horizons--alternative routes for insulin therapy

1 reference

12 December 2020

Novel insulins: expanding options in diabetes management

1 reference

12 December 2020

At last, a weight neutral insulin?

1 reference

12 December 2020

Insulin glulisine. Aventis Pharma.

1 reference

12 December 2020

Inhaled human insulin treatment in patients with type 2 diabetes mellitus

1 reference

12 December 2020

The impact of the diabetes control and complications trial and humalog insulin on glycohemoglobin levels and severe hypoglycemia in type 1 diabetes

1 reference

12 December 2020

1 reference

12 December 2020

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

1 reference

12 December 2020

Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: the glucose stabilization effects of HIM2.

1 reference

12 December 2020

Role of the IGF-I receptor in mutagenesis and tumor promotion

1 reference

12 December 2020

Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus

1 reference

12 December 2020

Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes

1 reference

12 December 2020

Insulin glargine: an updated review of its use in the management of diabetes mellitus

1 reference

12 December 2020

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

1 reference

12 December 2020

Perioperative management of type 1 diabetes mellitus

1 reference

12 December 2020

Insulin Detemir Is Characterized by a Consistent Pharmacokinetic Profile Across Age-Groups in Children, Adolescents, and Adults With Type 1 Diabetes

1 reference

12 December 2020

A superactive insulin: [B10-aspartic acid]insulin(human).

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model

1 reference

12 December 2020

Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group.

1 reference

12 December 2020

How long should insulin be used once a vial is started?

1 reference

12 December 2020

Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs

1 reference

12 December 2020

Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group.

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

1 reference

12 December 2020

Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects

1 reference

12 December 2020

Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial

1 reference

12 December 2020

Clinical pharmacology of human insulin

1 reference

12 December 2020

Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.

1 reference

12 December 2020

Hyperinsulinemia as an independent risk factor for ischemic heart disease.

1 reference

12 December 2020

Effectiveness of postprandial Humalog in toddlers with diabetes.

1 reference

12 December 2020

[Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin

1 reference

12 December 2020

Development of oral insulin: progress and current status

1 reference

12 December 2020

Insulin analogues. A critical review.

1 reference

12 December 2020

Standards of medical care in diabetes

1 reference

12 December 2020

Insulin glargine: long-acting basal insulin analog for improved metabolic control

1 reference

12 December 2020

Glargine insulin is not an alternative in insulin allergy

1 reference

12 December 2020

A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes

1 reference

12 December 2020

Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor

1 reference

12 December 2020

The rationale and management of hyperglycemia for in-patients with cardiovascular disease: time for change

1 reference

12 December 2020

Advances in the treatment of diabetes-insulin analogues.

1 reference

12 December 2020

Albumin binding and time action of acylated insulins in various species

1 reference

12 December 2020

Clinical significance, pathogenesis, and management of postprandial hyperglycemia

1 reference

12 December 2020

1 reference

12 December 2020

Intensive insulin therapy in critically ill patients

1 reference

12 December 2020

Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin.

1 reference

12 December 2020

Evaluation of the reproductive toxicity and embryotoxicity of insulin glargine (LANTUS) in rats and rabbits

1 reference

12 December 2020

A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes

1 reference

12 December 2020

Long-acting insulin analogs.

1 reference

12 December 2020

Is insulin resistance the principal cause of type 2 diabetes?

1 reference

12 December 2020

A rational approach to drug therapy of type 2 diabetes mellitus

1 reference

12 December 2020

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

12 December 2020

Comparison of an insulin analog, insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus

1 reference

12 December 2020

Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus

1 reference

12 December 2020

Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304

1 reference

12 December 2020

Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I.

1 reference

12 December 2020

Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes

1 reference

12 December 2020

The safety and efficacy of insulin analogs in pregnancy

1 reference

12 December 2020

Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus

1 reference

12 December 2020

Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study

1 reference

12 December 2020

Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart

1 reference

12 December 2020

Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with Type 1 diabetes.

1 reference

12 December 2020

Insulin lispro: a pharmacoeconomic review of its use in diabetes mellitus

1 reference

12 December 2020

The human insulin analogue aspart is not the almighty solution for insulin allergy

1 reference

12 December 2020

Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group.

1 reference

12 December 2020

Insulin glargine: a systematic review of a long-acting insulin analogue

1 reference

12 December 2020

Insulin lispro therapy in pregnancies complicated by type 1 diabetes: glycemic control and maternal and fetal outcomes

1 reference

12 December 2020

Effect of continuous subcutaneous insulin infusion vs multiple daily insulin injection with glargine as basal insulin: an open parallel long-term study

1 reference

12 December 2020

Comparison of metabolic deterioration between insulin analog and regular insulin after a 5-hour interruption of a continuous subcutaneous insulin infusion in type 1 diabetic patients

1 reference

12 December 2020

Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use

1 reference

12 December 2020

LysB3, GluB29 insulin: a novel insulin analog with enhanced β-cell protective action

1 reference

12 December 2020

Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes

1 reference

12 December 2020

Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group

1 reference

12 December 2020

Recombinant DNA technology in the treatment of diabetes: insulin analogs

1 reference

12 December 2020

Insulin storage in Europe: a comment to Grajower et al., Eli Lilly, and Novo Nordisk

1 reference

12 December 2020

Drug therapy of postprandial hyperglycaemia.

1 reference

12 December 2020

Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice.

1 reference

12 December 2020

10.2165/00003495-200565030-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

11 August 2017

1035178917

0 references

1 reference